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Systems that evolve over time and follow mathematical laws as they evolve are called dynamical systems.
Lymphocyte recovery and clinical outcomes in 41 allograft recipients conditioned using antithymocyte
globulin (ATG) and 4.5-Gy total body irradiation were studied to determine if immune reconstitution could be
described as a dynamical system. Survival, relapse, and graft-versus-host disease (GVHD) were not signiﬁ-
cantly different in 2 cohorts of patients receiving different doses of ATG. However, donor-derived CD3þ cell
reconstitution was superior in the lower ATG dose cohort, and there were fewer instances of donor
lymphocyte infusion (DLI). Lymphoid recovery was plotted in each individual over time and demonstrated 1
of 3 sigmoid growth patterns: Pattern A (n ¼ 15) had rapid growth with high lymphocyte counts, pattern B
(n ¼ 14) had slower growth with intermediate recovery, and pattern C (n ¼ 10) had poor lymphocyte
reconstitution. There was a signiﬁcant association between lymphocyte recovery patterns and both the rate of
change of donor-derived CD3þ at day 30 after stem cell transplantation (SCT) and clinical outcomes. GVHD
was observed more frequently with pattern A, relapse and DLI more so with pattern C, with a consequent
survival advantage in patients with patterns A and B. We conclude that evaluating immune reconstitution
after SCT as a dynamical system may differentiate patients at risk of adverse outcomes and allow early
intervention to modulate that risk.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stem cell transplantation (SCT) results in
widely disparate outcomes in individual transplant re-
cipients, regardless of uniformity of histocompatibility
criteria applied in donor selection [1-3] and therapeutic
interventions [4-6] used for pretransplant conditioningdgments on page 1245.
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ty for Blood and Marrow Transplantation.regimens and graft-versus-host disease (GVHD) prophy-
laxis. Standard methodology is to examine clinical out-
comes using statistical analytic techniques based on
probability theory [7,8]. These analytic techniques are
useful in determining odds of clinical outcomes in pop-
ulations of patients transplanted using uniform condi-
tioning regimens but are inadequate for determining the
course an individual might take after SCT. This is because
of the underlying assumption that within the constraints of
certain critical parameters, such as donor type or HLA
matching, the probability distribution of these clinical
outcomes is essentially random. As an example, the
Table 1
Patient Characteristics
ATG 5.1 ATG 7.5
N 19 22
Male 12 14
Median age (range) 57 (44-69) 57 (40-68)
Donor
Matched related donor 9 10
Unrelated donor 10 12
HLA Mismatch 2 2
Stem cell source
Bone marrow 2 2
Peripheral blood 17 20







Median no. of prior regimens (range) 4 (2-10) 4 (1-15)
Prior autologous SCT 6 8
Median cell dose infused
CD3þ  106/kg (range) 2.3 (.1-5.7) 2.9 (.2-11.3)
CD34þ  108/kg (range) 5.8 (1.7-10.4) 5.1 (1.6-7.5)
MM indicates multiple myeloma; NHL, non-Hodgkin lymphoma; AML,
acute myelogenous leukemia; MDS, myelodysplastic syndrome; CLL,
chronic lymphocytic leukemia; PLL, prolymphocytic leukemia.
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tioning regimen reduces the likelihood of developing se-
vere acute GVHD [9], and higher levels of donor T cell
chimerism at day 30 after reduced-intensity conditioning
(RIC) results in a lower probability of relapse after SCT [10].
Such population-based estimates are used to guide clinical
decision-making at various time points during the trans-
plant process, but individual patients undergoing SCT
remain at risk for competing causes of adverse outcomes.
To improve outcome predictions in individuals undergo-
ing SCT in real time, a closer examination of the immu-
nobiology of transplantation is necessary. In SCT treatment,
failure is often attributable to either the development of
immune-mediated GVHD or the lack of an immune graft-
versus-malignancy (GVM) effect [11-16]. Donor-derived im-
mune reconstitution is driven, in part, by the disparity in
minor histocompatibility antigens encountered in each
instance of SCT [17,18]. It has been demonstrated that HLA-
matched donorerecipient pairs have extensive variation in
their exomes [19]. When analyzed in silico, this translates to
a massive array of minor histocompatibility antigens, which
may be presented by the HLA in the recipients [20]. This
minor histocompatibility antigen difference may be consid-
ered an alloreactivity potential between donors and recip-
ient pairs and appears to mirror the complex T cell clonal
frequency observed in the T cell repertoire in SCT donors and
recipients [21]. This suggests that clinical outcomes related
to T cell alloreactivity after SCT may not be primarily sto-
chastic in nature but when taking a quantitative perspective
may be better considered mathematically to account for the
large alloreactivity potential between SCT donors and
recipients.
Systems that follow mathematically deﬁned laws are
common in the natural world and are called dynamical
systems [22-25]. A dynamical system is deﬁned as any
iterating physical system that evolves over time in a manner
such that future states of the system are predicated on all the
preceding states and the evolution of the system can be
modeled using ordinary differential equations. Population
growth constrained by environmental pressures is a
nonlinear example of such a system. In the context of SCT,
this implies that if considered as a system of interacting
donor T cell clones and recipient antigens, immune recon-
stitution after SCT is a dynamic, evolving process that can be
modeled mathematically and allow more precise determi-
nation of the odds of clinical outcomes, such as engraft-
ment, GVHD, and survival, in an individual [26]. A feature of
dynamical systems is that early events in the system set the
trajectory of the series of events to follow and thus deter-
mine the eventual outcome. In nonlinear dynamical sys-
tems, this implies that small variations in the early state of
the system can produce large measurable effects late in the
evolution of this system. In SCT a large body of literature
now supports the notion that both early interventions [27-
29] and the magnitude of immune reconstitution early in
the course of SCT impacts late clinical outcomes [13,30,31],
supporting the validity of considering SCT as a nonlinear
dynamical system.
In this article the results of a prospective, randomized,
phase II clinical trial are reported and considered in the light
of immune reconstitution kinetics modeled as a dynamical
system. The trial investigated 2 doses of rabbit ATG (Thy-
moglobulin; Sanoﬁ-Aventis, Quebec, Canada) in patients
undergoing RIC. The trial was designed to determine the
optimal dosing of ATG to be given in combination withreduced-intensity total body irradiation (TBI) to ensure
adequate engraftment. The clinical outcomes from this trial
are analyzed with an underlying assumption that each
transplant represents an example of a dynamical system.
Each donorerecipient pair is composed of a unique set of
recipient alloantigens and a set of donor-derived immune
effectors interacting over time after the transplant event, in
this instance modulated by 2 different ATG doses. The focus
of the work presented here is on total lymphoid and T cell
reconstitution and the resulting clinical effect. We demon-
strate that lymphoid reconstitution after transplantation
follows the ubiquitous quantitative rules describing con-
strained growth, that is, it occurs as a logistic function of
time.METHODS
Patients
Between 2009 and 2013, 41 patients were enrolled in a prospective,
randomized, phase II clinical trial, approved by the institutional review
board at Virginia Commonwealth University (ClinicalTrials.gov Identiﬁer:
NCT00709592). To be eligible, patients had to be 70 years old with
recurrent or high-risk hematological malignancy. Patients were required to
have a 7/8 or 8/8 locus matched related or unrelated donor, with high-
resolution typing performed for HLA-A, -B, -C, and -DRB1. Two different
doses of ATG were tested in the 2 arms of this trial, and patients were
stratiﬁed for donor type (matched related or unrelated donor) and disease
status (ﬁrst complete remission or higher) at the time of randomization.
Patient characteristics are given in Table 1. Patient follow-up was updated as
of October 2014.Rabbit ATG and Low-Dose TBI Conditioning Regimen
Patients were randomized between 2 different doses of rabbit ATG,
either 2.5 or 1.7 mg/kg, adjusted ideal body weight per day given intrave-
nously from day 9 to 7 (ATG 7.5 or ATG 5.1 cohorts), followed by TBI to a
total dose of 4.5 Gy, delivered in 3 1.5-Gy fractions, administered twice on
day 1, with the ﬁnal dose on day 0 (see Supplemental Figure 1 and
Supplemental Material). Tacrolimus given orally for GVHD prophylaxis
from day 2, with taper commencing around 12 weeks post-transplant, in
an initial cohort of patients (n ¼ 24) and according to donor-derived T cell
counts in the remaining patients. Mycophenolate mofetil (MMF) was given
orally at a dose of 15 mg/kg twice daily from days 0 to 30. Escalating-dose
donor lymphocyte infusion (DLI) was permitted beyond 8 weeks post-SCT
A.A. Toor et al. / Biol Blood Marrow Transplant 21 (2015) 1237e1245 1239for the management of declining or persistent mixed chimerism and for
disease progression.
Lymphoid Reconstitution after SCT
Absolute lymphocyte counts (ALCs, mL1), measured at multiple time
points as a part of routine clinical care of the patients after SCT, were plotted
over time and analyzed using GraphPad Prism version 6.00 for Windows
(GraphPad Software, La Jolla, CA). These data were examined for trends over
time and further analyzed as a logistic function of time using the equation of
the general form,Nt¼N0þ (KN0)/(1þ10(at)R) (adopted from Prismversion
6.00). In this equation, N0 represents the lymphocyte count at the beginning,
K is the lymphocyte count at steady state, Nt is the lymphocyte count at time
t after transplant, a is the time at which growth rate is maximal and an
inﬂection point is observed in the logistic curve, and R is the growth rate of
the population. To elucidate the initial growth followed by exponential
expansion of the lymphocytes and to eliminate the effect of extraneous
therapy on lymphocyte counts (eg, corticosteroids for GVHD, chemotherapy
for relapse, cytomegalovirus reactivation, and therapy), these parameters
were determined only for the time post-transplant before these clinical
events had transpired. ALCs after DLI were not considered as a part of this
analysis.
T Cell Engraftment Analysis
Donor engraftment was measured using chimerism analyses per-
formed at approximately 4, 8, 12, and 24 weeks after transplant on
immunomagnetically separated granulocytes and total T cells as previously
described [13]. Donor-derived CD3þ T cell count (ddCD3) was calculated by
multiplying the T cell chimerism (% recipient DNA, expressed as a fraction)
with the absolute blood CD3þ T cell count obtained simultaneously. The
resulting absolute recipient-derived CD3þ T cell count was then subtracted
from the total absolute CD3þ cell count to obtain a ddCD3. When available,
the calculated ddCD3 values for the ﬁrst 3 to 6 months were plotted over
time for each patient as a polynomial (cubic) function of time (y ¼ ax3 þ
bx2 þ cx þ d) using Microsoft Excel software (Microsoft Corporation,
Redmond, WA). This was done with the assumption that the ddCD3 on day
0 of SCT will be zero. From the resulting polynomial equations for each
patient, the differential equation describing the rate of change of ddCD3 at
any time point along the curve for each patient was determined (dy/dx ¼
3ax2 þ 2bx þ c). The derivative (ie, rate of change of ddCD3 at days 30 and
45) was then calculated for each individual using Wolfram/Alpha Online
Derivative Solver (Wolfram/Alpha LLC, Champaign, IL). These early points
were chosen because they represented the earliest clinically important
measured ddCD3 value available and because these allowed determination
of the T cell expansion rate in the time period immediately after the
cessation of MMF. The derivative calculations were also conﬁrmed by
manual calculations.
Study Design and Statistical Analysis
For this analysis overall survival was taken from the day after trans-
plant to the day of death. GVHD was classiﬁed according to consensus
criteria. Acute GVHD was graded according to the Glucksberg criteria.
GVHD observations were censored if this complication developed after DLI.
Disease-speciﬁc criteria were used for diagnosing relapse or progression.
Survival and event-free survival curves (relapse-fatality) for the 5.1- and
7.5-level dose groups were plotted with Kaplan-Meier curves and
compared using the log-rank test. The incidence curves for relapse, acute
GVHD, chronic GVHD, and DLI use (accounting for the competing risk of
mortality) were plotted and compared between dose levels using Grey’s
test. Wilcoxon rank sum tests were used to compare median percentage
chimerism and ddCD3 cell count between dose groups at different times
after SCT; this nonparametric test was used because these measures
exhibit highly nonsymmetrical distributions. The R statistical software
(version 2.15; Revolution Analytics, Mountain View, CA ) was used for all
time-to-event analyses, with the survival package used for survival curves
and the cmprsk package used for all competing risk curves.
The rate of change in ddCD3 cell count at day 30 (dx/dy(30)) and day 45
(dx/dy(45)) after SCT was summarized with medians and interquartile
ranges for each level (yes/no) of the following clinical outcomes: GVHD,
relapse, survival, and DLI use. The Wilcoxon rank sum test was used to
compare medians in dx/dy(30) and dx/dy(45) between the levels of those
health outcomes and other variables studied. A 5% signiﬁcance level was
used for purposes of testing null hypotheses that these values are equal
across the 2 levels of the clinical outcomes versus 2-sided alternative hy-
potheses. The Kruskal-Wallis test was used to compare monocyte count
medians between lymphocyte recovery patterns. A 5% signiﬁcance level was
used for purposes of testing null hypotheses, and a Bonferroni-adjusted
level of .1067 ws used in cases of multiple comparisons between logistic
characteristic patterns. The NPAR1WAY procedure was used in the SASstatistical software (version 9.4; SAS Institute, Cary, NC) for all analyses. The
Pearson correlation coefﬁcient was used to measure the relationship be-
tween logistic growth patterns in lymphocyte recovery and CD3þ dose,
CD34þ dose, and tacrolimus level area under the curve.
RESULTS
Clinical Outcomes with ATGþTBI Conditioning
This study was designed to examine the relative impact of
2 ATG doses in a RIC regimen on immune reconstitution and
subsequent clinical outcomes, with the aim of improving
survival by limiting fatal GVHD while retaining GVM effects.
At last follow-up there were no signiﬁcant differences in the
survival between the 2 study arms (log-rank P ¼ .53)
(Figure 1A). The 1- and 2-year survival rates in the ATG 5.1
cohort were both 71.3% (standard error [SE] ¼ 1.1%), whereas
those in the 7.5 cohort were 90.9% (SE ¼ .4%) and 62.4%
(SE ¼ 1.2%), respectively.
The conditioning regimenwas tolerated well with no day
100 transplant-related mortality observed. The treatment-
related mortality rate and relapse rate were not signiﬁ-
cantly different between the 2 dose groups (Grey’s test P ¼
.82 and .62, respectively) (Figure 1B). The 1- and 2-year
relapse rates in the ATG 5.1 cohort were 21.8% (SE ¼ .8%)
and 28.0% (SE ¼ 1.1%), respectively, and in the ATG 7.5 cohort
were 40.9% (SE ¼ 1.2%) and 50.0% (SE ¼ 1.2%), respectively.
Event-free survival was also comparable between the 2 arms
(P ¼ .76) (Figure 1C).
Accounting for the competing risk of mortality, acute
GVHD rate in the ATG 5.1 cohort was 27.2% (SE¼ 1.0%) and in
the 7.5 dose group 4.5% (SE ¼ .2%) (P ¼ .039) (see
Supplemental Material for details). Similarly, accounting for
the competing hazard of mortality, the 1- and 2-year chronic
GVHD rates in the ATG 5.1 cohort were both 23.8% (SE¼ .94%)
and in the ATG 7.5 group 31.8% (SE ¼ 1.1%) and 36.8%
(SE ¼ 1.2%), respectively (P ¼ .37) (Figure 1D).
Theneed for post-transplant cellular therapy intervention,
DLI (administered for either mixed chimerism or persistent
disease or relapse)was greater in theATG7.5 arm. Accounting
for the competing risk ofmortality, the 1- and 2-yearDLI rates
in the ATG 5.1 armwere both 8.9% (SE ¼ .4%), whereas in the
ATG 7.5 arm it was 40.9% (SE ¼ 1.1%) and 45.5% (SE ¼ 1.2%),
respectively (Grey’s test P ¼ .072) (Figure 1E).
Engraftment
To determine the dose effect of ATG on T cell and myeloid
engraftment in this RIC regimen, T cell chimerism and abso-
lute T cell count recovery and granulocyte chimerism were
compared between the 2 arms. T cell chimerism was mixed
donorerecipient in a number of patients, with a larger
recipient-derived component in the ATG7.5 cohort compared
with the ATG 5.1 cohort, except at 9 months (where both
medians were 0) (Table 2). Correspondingly, the ddCD3 cell
counts were higher in the ATG 5.1 cohort than in the ATG 7.5
cohort at every time point (Supplemental Figure 2, Table 2).
Myeloid engraftment was donor derived in all but 3 patients
in the ATG 7.5 cohort. These results demonstrate that he-
matopoietic engraftment was superior in the ATG 5.1 cohort.
Lymphoid Reconstitution Kinetics
To study the inﬂuenceof the rateof immune reconstitution
on clinical outcomes in individual patients, ALCs (mL1) for
each individual were plotted over time to model immune
reconstitution kinetics. Similar to population growthmodels,
lymphocyte recovery after SCT occurred as a logistic function
of time. In a number of patients, 2 discernable periods of
Figure 1. Clinical outcomes in the ATG 5.1 and ATG 7.5 cohorts. (A) Kaplan-Meier survival curves. (B) Cumulative incidence curves for relapse (competing risk of
transplant-related mortality). (C) Kaplan-Meier event-free survival (relapse and fatality). (D) Cumulative incidence curves for chronic GVHD, observations censored at
DLI (competing risk of fatality without GVHD). (E) Cumulative incidence curve for DLI (competing risk of fatality).
A.A. Toor et al. / Biol Blood Marrow Transplant 21 (2015) 1237e12451240exponential increase in ALC were observed, 1 after engraft-
ment and another period after cessation of MMF (Figure 2A,
Supplemental Figure 3). These growth periods were each
followed by a plateau, representing the steady state immune
cell recovery at that phase of SCT, with relatively stable
lymphocyte counts in the absence of clinical events until
withdrawal of tacrolimus, when greater variability was
observed, and a trend of a further increase in ALC was
frequently observed. On examination of individualTable 2
Median Percentage Recipient Chimerism (Top) and ddCD3 Cell Counts (Bottom) by
Time Post-SCT
1 mo 2 mo 3 m
ATG 7.5 6.7 8.8 18
ATG 5.1 .0 1.0 1
P on differences .20 .16
ATG 7.5 93.3 105.8 92
ATG 5.1 214.1 576.6 405
P on differences .068 .073
* Statistically signiﬁcant at P<.05.lymphocyte recovery plots, 3 general patterns of lymphoid
recovery were observed over time (Figure 2B): pattern A (n¼
15), sigmoid growth with early, rapid lymphoid expansion
andahigh steady state level (ALC>1000mL1, inﬂectionpoint
< 60 days post-SCT); pattern B (n ¼ 14), a lower steady state
level arrived at slowly (ALC  500 to 1000 mL1, inﬂection
point > 60 days); and pattern C (n ¼ 10), poor ALC recovery
withminimal to no discernable sigmoid growth kinetics (ALC
< 500 mL1). Two patients from the ATG 7.5 cohort with goodATG Dosing Cohort and Time Post-SCT
o 6 mo 9 mo 12 mo
.5 8.7 .0 1.4
.5 .0 .0 .0
.024* .056 .052 .077
.1 225.7 352.0 493.0
.0 408.0 853.7 680.0
.031* .63 .071 .18
Figure 2. ALC (mL1) recovery after ATGþTBI and SCT. (A) Two periods of growth are seen, ﬁrst from days 0 to 30 when patients are on MMF (blue outline) and the
second from day 20 to approximately day 120 (orange outline). Each period demonstrates an initial phase of slow growth, followed by exponential expansion and
ﬁnally relatively stable counts, until tacrolimus is discontinued, when greater variability is observed. Data from a matched related donor (MRD) and an unrelated
donor (URD) SCT are shown. (B) Logistic dynamics of lymphoid recovery after SCT. Three patterns are observed corresponding to high, pattern A; intermediate,
pattern B; and slow growth rate, pattern C.
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cell chimerism were excluded from this analysis. Patients
developing complications of therapy such as relapse, viral
reactivation (cytomegalovirus or Epstein-Barr virus), and
GVHD requiring corticosteroid therapy had signiﬁcant de-
partures from the sigmoidal curve generally after reaching a
plateau (Supplemental Figure 3). Logistic curve ﬁtting pa-
tients with pattern A demonstrated the double exponential
expansion periods (median R2, .90 and .89, respectively, n ¼
15), withmedian growth exponent (R in the logistic equation)
values of .94 and .18 for the 2 periods, respectively. Pattern B
patients similarly demonstrated logistic growth (median R2,
.83, n ¼ 14), albeit with a much slower growth rate of .04.
Logistic patterning was signiﬁcantly associated with all
clinical outcomes, including survival in 67% versus 86%
versus 30% of patients in pattern A, B, and C groups,
respectively (exact test P value ¼ .0189); relapse in 33%, 29%,
and 90% (P ¼ .0053); cumulative GVHD in 67%, 43%, and 10%
(P ¼ .0198); and DLI use in 13%, 21%, and 70% of patients,respectively (P ¼ .0069). Pattern C patients had a particularly
poor outcome in terms of survival, relapse, and need for DLI.
Determinants of Logistic Patterning
To identify factors inﬂuencing logistic growth patterns
observed in lymphocyte recovery (ATG dose, donor type and
age, diagnosis, prior therapy, CD3þ and CD34þ cell doses
infused), tacrolimus level area under the curve for days 15,
30, and 60 were reviewed and did not demonstrate statisti-
cally signiﬁcant association with the ALC curve logistic pat-
terns recorded. Reasoning that the lymphocyte growth
exponent, R, for T cells will be inﬂuenced by antigen pre-
sentation before the period of exponential growth, the
monocyte recovery curves after SCT were plotted for each
individual and overlaid with the T cell expansion curve. After
engraftment, there was correspondence in the lymphocyte
and monocyte growth curves, both demonstrating logistic
dynamics (Figure 3A, Supplemental Figure 4). Furthermore,
there was a strong association between the maximal
Figure 3. Determinants of lymphoid recovery. (A) Correspondence of early monocyte recovery with lymphocyte reconstitution, association of high early monocyte
recovery with late lymphoid expansion (orange circles indicate monocytes; black diamonds, lymphocytes) plotted against days post-SCT. (B) ddCD3 cell count plotted
over time, and derivative for the polynomial curve determined at days 30 and 45. Derivative is the slope of the tangent to the polynomial curve (dy/dx) and gives the
approximate rate of change of ddCD3 at that point in time. Accuracy of the derivative depends on the goodness of ﬁt of the polynomial curve.
A.A. Toor et al. / Biol Blood Marrow Transplant 21 (2015) 1237e12451242circulating monocyte counts (mL1) recorded between days
12 and 16 (periengraftment) and the logistic patterns
observed in lymphocyte recovery over the ﬁrst 3 months
post-transplant; these values were 600, 350, and 200,
respectively, in patients with lymphocyte recovery patterns
A, B, and C (P ¼ .0002). Robust monocyte recovery post-
engraftment may be associated with greater likelihood of
recipient (and microbial) antigen presentation in the earliest
days after SCT, yielding higher values of R and faster
lymphocyte expansion.
Donor-Derived T Cell Recovery Kinetics
To identify the cell subset associated with lymphoid
expansion and to determine the effect of donor-derived T cell
recovery kinetics on clinical outcomes, the ddCD3 counts
were plotted as a function of time for the ﬁrst 6 months after
SCT for patients for whom data were available. Using theequation for the resulting curves, the derivative equation of
each curvewas then calculated to allow the determination of
an approximate, instantaneous rate of change of ddCD3 at
various times along the plotted curve (Figure 3B). The de-
rivative of this curve for each patient dx/dywas calculated for
days 30 and 45 post-SCT to assess the impact of early T cell
reconstitution on clinical outcomes. The dx/dy values ob-
tained in this ATG conditioned set of patients for days 30 and
45 were highly correlated with each other (Spearman’s cor-
relation coefﬁcient, R2 ¼ .91). They also correlated with the
logistic patterns of ALC recovery observed in each patient,
suggesting the exponential expansion observed in the ALC
may be due to ddCD3 proliferation. Both the dx/dy(30) and
dx/dy(45) medians were signiﬁcantly different between
logistic classiﬁcations (Table 3); speciﬁcally, patients with
pattern A logistic lymphoid recovery had higher dx/dy(30)
compared with those demonstrating both pattern B
Table 3
Correlation of Rate of Change in ddCD3 Cell Counts at Days 30 and 45 with
ALC Recovery Logistic Patterns
Logistic
pattern
dx/dy(30) ddCD3 dx/dy(45) ddCD3
n Median IQR n Median IQR
A 14 15.5 12.2, 25.2 14 10.8 1.4, 17.3
B 14 2.5 .4, 3.9 14 1.5 .6, 26
C 5 .2 .1, .5 5 .1 .1, .5
P < .0001 P ¼ .0015
A.A. Toor et al. / Biol Blood Marrow Transplant 21 (2015) 1237e1245 1243(P ¼ .0014) and pattern C (P  .001). For dx/dy(45), pattern C
patients had signiﬁcantly lower levels than both pattern A
(P ¼ .0063) and pattern B patients (P ¼ .0063) (using
Bonferroni-adjusted signiﬁcance level of .0167). This sug-
gests the exponential expansion observed in the lymphocyte
recovery patterns was attributable to ddCD3 proliferation.
And even though instantaneous measures of ddCD3 cell
expansion, the day 30 and 45 ddCD3 derivative measure-
ments generally correlated with clinical outcomes (Table 4).
This measure at day 30 was signiﬁcantly different between
patients experiencing GVHD (P ¼ .0026) and those requiring
DLI (P ¼ .0476), indicating the inﬂuence of early donor T cell
expansion on alloreactivity.
DISCUSSION
Patients undergoing HLA matched allogeneic SCT are at
risk for competing hazards of relapse, nonrelapse mortality,
and alloreactivity (ie, GVHD or graft rejection), potentially
leading to treatment failure [32]. Beyond tumor biology, the
2 most critical factors inﬂuencing treatment failure are
regimen-related toxicity of the SCT and T cell reconstitution
after transplantation, with its effects on alloreactivity and
opportunistic infections. Once regimen-related toxicity is
diminished using RIC regimens, the ability to forecast and
manage the restoration of T cell immunity would be of great
value in terms of optimizing clinical outcomes. In this study
we found that T cell reconstitution after SCT is a dynamic
process that can be modeled by equations commonly used to
describe growth in biological systems. Furthermore, the dy-
namics of T cell reconstitution have a major impact on
important clinical outcomes such as GVHD and engraftment
as well as survival. This suggests that the likelihood of certain
clinical outcomes may be computed in real time during the
course of SCT and appropriate therapeutic adjustments made
dynamically, rather than at speciﬁc time points post-
transplant.
Systems following logistic dynamics, modeling con-
strained growth, depicted by the sigmoid curve, are commonTable 4
Correlation of Day 30 and Day 45 ddCD3 Derivative Values and Clinical
Outcome on Patients in whom Data was Available to Allow Plotting of the
Polynomial Curve
Yes No P
n Median IQR n Median IQR
dx/dy(30)
GVHD 16 14.5 4.4, 16.5 17 .9 .1, 5.5 .0026
Relapse 14 2.3 .1, 10.9 19 4.7 2.1, 16.0 .0869
Survival 22 4.5 .9, 15.6 11 3.7 .3, 15.5 .8635
DLI use 9 .9 .1, 5.2 24 7.1 1.4, 16.5 .0476
dx/dy(45)
GVHD 16 3.4 1.2, 13.5 17 .7 .3, 2.3 .0562
Relapse 14 1.6 .4, 6.9 19 1.8 .9, 10.9 .4888
Survival 22 1.6 .8, 6.5 11 1.9 .1, 15.6 .9848
DLI use 9 .5 .3, 2.0 24 2.1 .9, 13.2 .1149in biology [22,23], describing phenomenon as diverse as
population growth (in both the microbial and in the animal
kingdom) and enzyme reaction kinetics with saturation. The
hypothesis that they should also describe lymphocyte
reconstitution after an immunoablative SCT is rational and
supported by our data. Further support for this concept
comes from the observation that, as expected, clinical events
such as GVHD and infections and relapse lead to a departure
from steady state behavior evident in these curves. An
important consideration in reviewing the ALC data presented
here is that many different immune cell subsets constitute
these curves, natural killer cells, T cell subsets, and B cells,
with all the cell subsets following different growth kinetics;
therefore, the ALC growth curves seen here are an average of
all those inﬂuences. Correlation of these growth curves with
donor-derived T cell counts, however, makes it evident that
this constitutes the dominant immune cell population
leading to the late exponential growth (after cessation of MMF
in the second month after SCT with this regimen) and its
subsequent inﬂuence on long-term clinical outcome,
whether it be GVHD after withdrawal of immunosuppression
or long-term disease control. Once again supporting this idea
is the observation of eventual relapse and DLI need in pa-
tients who did not experience this late lymphoid/ddCD3 cell
expansion.
There are important clinical implications of this dynam-
ical system modeling of SCT, the most important is that it
identiﬁes subgroups of patients at greater risk for certain
transplant outcomes over others (relapse or GVHD),
increasing the predictability of the clinical course likely to be
observed in individual SCT recipients. For instance, patients
with logistic pattern A, or with a high rate of change of
ddCD3 at day 30 in our 2 cohorts, were more likely to
develop late onset acute or chronic GVHD when immuno-
suppression was withdrawn. Patients with logistic pattern C
were more likely to require DLI or to relapse. This behavior
suggests that plotting ALC and/or ddCD3 in the ﬁrst few
weeks after SCTmay allow categorization of patients into risk
groups based on dynamic immune reconstitution. Future
interventions may then be planned accordingly. This may
include prolonged immunosuppression with tacrolimus in
those with high derivative ddCD3 values or closer moni-
toring and pre-emptive therapy for cancer relapse in those
with lower values.
Certain dynamical systems demonstrate strong inﬂuence
of early conditions on late outcomes. To understand this,
consider an idealized situation where the natural killer cell
and B cell effect on clinical outcome is negligible and clinical
outcomes, such as GVHD, GVM (considering standard risk
malignancy in a minimal residual disease state), and
engraftment, are a function of T cell reconstitution. Here, the
T cell population, Ntþ1, at time, t þ1 after SCT, is a function of
the Tcell populationNt, at an earlier time point, t. This in turn
will be dependent on the T cell population at the outset of









In this model (Figure 4) the ﬁnal steady state population
of T cells, K, and its clonal repertoire will have a major in-
ﬂuence on clinical outcomes. An approximation of this
growth rate for donor-derived T cells at various times after
SCT is provided by the derivative we calculated. In this model
initial conditions (ie, N0 and R) impact the trajectory of
Figure 4. Logistic model of lymphocyte proliferation post-transplant. Cell dose
infused at the time of SCT N0 will start proliferating under the inﬂuence of the
driving parameter R and expand over time t, taking on values of Nt, Ntþ1,.,
Ntþn. This will include a period of exponential expansion as the lymphopenic
state after SCT is corrected and eventually a stable lymphocyte population K is
established. Changes in antigen presentation (due to infection, tissue injury)
and immunosuppression levels and the overall cytokine milieu may perturb
the steady state or growing populations by altering R and result in greater
variability seen at speciﬁc time points. Reconstitution of the lymphocyte
subset populations by differentiation of hematopoietic cells also changes N.
The curves represents an average of the lymphoid cell populations (and
clones) seen in circulation, with each population repopulating with similar
dynamics but at different rates. Three other hypothetical curves along the
continuum of logistic expansion are also shown with different N0 (not evident
due to scale) and R values (R > R1 > R2 > R3). Blue circles and top curve depict
data from an actual patient.
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chimerism and lower ddCD3 cell count observed several
months after the transplant in the ATG 7.5 cohort is consis-
tent with this initial effect. Although the population differ-
ences in clinical outcomes are not statistically signiﬁcant
between the 2 cohorts, it is noteworthy that an ATG dose
difference of 2.4 mg/kg may have an inﬂuence on immune
reconstitution and subsequent clinical outcomes, reﬂected
by absence of late acute GVHD and a greater need for DLI, as
well as graft loss in 3 individuals conditionedwith the higher
ATG dose. Presumably, this results from a higher ATG level at
the time of cell infusion, leading to lower in vivo N0 and also
potentially a lower value of R in these patients.
To understand the cellular basis of the relationship be-
tween immune cell reconstitution kinetics and clinical out-
comes (GVHD, relapse), it is important to recognize that the
ALC curves we obtained, as well as the ddCD3 curves,
represent an average measure of the proliferation of thou-
sands of different T cell clones, when deﬁned by T cell re-
ceptor speciﬁcity. These T cell clones are expected to follow
growth curves similar to this average growth curve recorded
in each individual but with different parameters. Further, the
expansion of ddCD3 cells would be in part dependent on
antigen presentation, with T cell clones presented with an-
tigen more likely to proliferate rapidly. Thus, in patients with
more robust hematopoietic recovery, it is likely that the
average value of R would be greater because antigen pre-
senting cell populations reconstitute faster. Considering
monocytes as a surrogate for antigen presenting cells, the
correspondence of early monocyte recovery with lymphoid
recovery patterns observed supports this hypothesis. In fact,
this may represent an example of interacting dynamical sys-
tems, where the R value in one drives the same in the other
system. Thus, the Rantigen presenting cell value may drive the
Reffector T cell by altering the cytokine concentrations in the
post-transplant milieu, with ambient immunosuppression
impacting both systems. The quantitative immune reconsti-
tution model described here is well known, with the familiarsigmoid growth kinetics of lymphocytes and by extension T
cell subsets and natural killer cells and the salutary effect of
early lymphoid recovery on clinical outcomes after SCT
[15,33]. The novelty of this work is in that it formalizes the
understanding of the nature of immune recovery post-
transplant as a dynamical system by clearly demonstrating
an exponential expansion of lymphocytes, which occurs at
variable rates.
This dynamical system modeling differs from stochastic
modeling of transplant outcomes in individuals because it
allows associations between immune reconstitution kinetics
and clinical endpoints (either freedom from GVHD or not). In
practice this would imply that immune cell subsets are
measured frequently in the ﬁrst few weeks after trans-
plantation in each SCT recipient. Rate of lymphoid reconsti-
tution at different times after SCT may then allow an
estimation of the likelihood of alloreactivity developing in
that speciﬁc patient and the corresponding clinical outcome.
The probability of the desired outcome, P at time tþ1, is
dependent on all states of the system leading up to the time t,
preceding tþ1; as explained above, the trajectory of the
system. This way clinical outcomes may be projected based
on the lymphocyte recovery kinetics observed in the ﬁrst few
weeks after SCT. On the other hand, in a stochastic model the
probability P of the desired outcome at time tþ1 is a function
of the probability distribution of the health state observed at
time t and is unaffected by states of the system leading up to
that time [34]. Therefore, an important advantage of
dynamical system modeling is that by active measurement
and intervention, this allows therapies to be modiﬁed on an
ongoing basis to achieve desired clinical outcomes. On the
other hand, conventional stochastic modeling allows selec-
tion of the optimal therapeutic program, but once the
treatment is initiated it can only predict the outcomes
observed based on prior probability distributions, allowing
only empiric therapeutic modiﬁcations. Dynamical system
modeling of immune reconstitution would allow true
personalization of patient management. Thus, patients with
the logistic pattern A would be more likely to have had rapid
oligoclonal expansion of alloreactive T cell clones andmay be
best managed with a prolonged course of immunosuppres-
sion to diminish the likelihood of delayed onset acute GVHD
or severe chronic GVHD [35]. Conversely, patients with
pattern Cwith limited Tcell clonal recoverymay beneﬁt from
early withdrawal of immunosuppression and DLI, before
conventional time points such as days 100 or 180 post-
transplant, to establish GVM effects before progression of
malignancy, especially in the context of RIC. These patients
may also beneﬁt from disease-speciﬁc post-transplant ther-
apies instituted along with planned DLI to prevent early
relapse. Patients with pattern B would be the most likely to
avoid life-threatening GVHD and have GVM develop given
the slower but more complete lymphoid reconstitution with
greater T cell clonal diversity. Next generation sequencing
techniques such as high-throughput sequencing of T cell
receptor b considered along with quantitative T cell recon-
stitution data discussed in this article will help further deﬁne
therapeutic needs. Integrating information about tumor
growth kinetics and donor recipient minor histocompatibil-
ity antigen differences will further help individualize thera-
peutic decision-making in the aftermath of SCT.
In conclusion, we demonstrate that immune reconstitu-
tion after SCT may be modeled mathematically using equa-
tions commonly used to describe population growth.
Immune reconstitution after other conditioning and GVHD
A.A. Toor et al. / Biol Blood Marrow Transplant 21 (2015) 1237e1245 1245prophylaxis regimens will in all likelihood follow the same
logistic dynamics but with different growth parameters.
Therefore, further study of quantitative T cell repertoire
reconstitution will allow determination of the degree to
which such measurement may be generalizable and as such
allow real time adjustments to be made in post-transplant
immunosuppression, resulting in optimal immunosuppres-
sion. Importantly, dynamical system modeling of transplant
makes it possible to limit the effect of randomness in pre-
dicting clinical outcomes such as GVHD and engraftment and
further reﬁne trial design by accounting for immune recon-
stitution kinetics.
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